

D13
140. (Amended) The antibody of claim 138, further comprising a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

D14
144. (Amended) The antibody of claim 142, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

D15
148. (Amended) The antibody of claim 146, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

D16
152. (Amended) The antibody of claim 150, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

D17
159. (Amended) The antibody of claim 157, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

245. (Amended) The antibody of claim 132 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2443.

246. (Amended) The antibody of claim 132 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2444.

247. (Amended) The antibody of claim 132 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2445.

19
254. (Amended) A substantially purified antibody that competes with a scFv antibody encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442 for binding to a human TANGO 268 antigen.

256. (Amended) The antibody of claim 132, 133 or 134, wherein the antibody is a monoclonal antibody.

257. (Amended) The antibody of claim 132, 133 or 134, wherein the antibody is a human antibody.

258. (Amended) The antibody of claim 132, 133 or 134, wherein the antibody is a humanized antibody.

220
259. (Amended) The antibody of claim 132, 133 or 134, wherein the antibody is a Fab fragment.

260. (Amended) The antibody of claim 132, 133 or 134, wherein the antibody is an scFv.

261. (Amended) The antibody of claim 132, 133 or 134, wherein the antibody is conjugated to a therapeutic or drug moiety.

262. (Amended) The antibody of claim 132, 133 or 134, wherein the antibody is conjugated to a detectable substance.

263. (Amended) A pharmaceutical composition comprising the antibody of claim 132, 133 or 134 and a pharmaceutically acceptable carrier.

264. (Amended) A kit comprising the antibody of claim 132, 133 or 134 and instructions for use, in one or more containers.